Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | MMP1 | P03956 | 2/20 | 0.37 |
| ▸ | MMP2 | P08253 | 2/20 | 0.37 |
| ▸ | MMP9 | P14780 | 2/20 | 0.37 |
| ▸ | MMP8 | P22894 | 2/20 | 0.37 |
| ▸ | MMP13 | P45452 | 2/20 | 0.37 |
| ▸ | F2 | P00734 | 3/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.34 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.34 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8370182 | 1.00 | KDM4E (0.42) | KDM4ECA2CA1MMP1MMP2 | |
| SCHEMBL18954349 | 0.98 | KDM4E (0.44) | KDM4ECA2CA1MMP1MMP2 | |
| SCHEMBL19677918 | 0.82 | KDM4E (0.40) | KDM4EMAPT | |
| SCHEMBL18971963 | 0.81 | KDM4E (0.42) | KDM4EMAPT | |
| SCHEMBL1318880 | 0.80 | CA2 (0.41) | KDM4ECA2CA1MMP1MMP2 | |
| SCHEMBL9963779 | 0.80 | KDM4E (0.41) | KDM4EMAPT | |
| SCHEMBL14477201 | 0.80 | KDM4E (0.41) | KDM4EMAPT | |
| SCHEMBL15326215 | 0.76 | KDM4E (0.38) | KDM4E | |
| SCHEMBL189725 | 0.76 | KDM4E (0.46) | KDM4EMAPT | |
| SCHEMBL22091484 | 0.76 | CA2 (0.36) | CA2CA1MMP1MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-6184354-A | — | — | None | — | — | JP | disclosed |
| US-7344704-B2 | Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of intravascular thrombi | SCHERING AG (DE) | 2008-03-18 | — | — | US | disclosed |
| EP-1307237-B9 | COMPLEXES CONTAINING PERFLUOROALKYL WITH POLAR RADICALS, METHOD FOR THE PRODUCTION AND USE THEREOF | BAYER SCHERING PHARMA AG (DE) | 2008-01-09 | — | — | EP | disclosed |
| EP-1088558-B1 | Galenic formulations comprising paramagnetic and diamagnetic compounds | BAYER SCHERING PHARMA AG (DE) | 2007-06-27 | — | — | EP | disclosed |
| US-7226578-B2 | Metal complexes that contain perfluoroalkyl, process for their production and their use in NMR diagnosis | SHERING AG (DE) | 2007-06-05 | — | — | US | disclosed |
| EP-1519756-B1 | USE OF METAL COMPLEXES CONTAINING PERFLUOROALKYL AS CONTRAST AGENTS IN MAGNETIC RESONANCE IMAGING FOR REPRESENTING INTRAVASCULAR THROMBI | BAYER SCHERING PHARMA AG (DE) | 2007-05-02 | — | — | EP | disclosed |
| EP-1307237-B1 | COMPLEXES CONTAINING PERFLUOROALKYL WITH POLAR RADICALS, METHOD FOR THE PRODUCTION AND USE THEREOF | BAYER SCHERING PHARMA AG (DE) | 2007-04-11 | — | — | EP | disclosed |
| US-20060093554-A1 | Galenical formulations | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-05-04 | — | — | US | disclosed |
| US-6916461-B2 | Metal complexes that contain perfluoroalkyl, process for their production and their use in NMR diagnosis | SCHERING AG (DE) | 2005-07-12 | — | — | US | disclosed |
| US-20050147563-A1 | Metal complexes that contain perfluoroalkyl, process for their production and their use in NMR diagnosis | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-07-07 | — | — | US | disclosed |
| EP-0845058-A1 | FIBROUS WEBS HAVING ENHANCED ELECTRET PROPERTIES | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1998-06-03 | — | — | EP | disclosed |
| WO-1997030969-A1 | PHARMACEUTICAL AGENTS CONTAINING PERFLUOROALKYL-CONTAINING METAL COMPLEXES AND THE USE THEREOF IN TUMOUR THERAPY AND INTERVENTIONAL RADIOLOGY | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-08-28 | — | — | WO | disclosed |
| WO-1997026017-A2 | PERFLUOROALKYL-CONTAINING METAL COMPLEXES AND THEIR USE IN NMR DIAGNOSTICS | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-07-24 | — | — | WO | disclosed |
| WO-1997007272-A1 | FIBROUS WEBS HAVING ENHANCED ELECTRET PROPERTIES | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1997-02-27 | — | — | WO | disclosed |
| US-5472481-A | Respirator having air filter compressing melt blown polypropylene microfibers and melt processable fluorochemical additive | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1995-12-05 | — | — | US | disclosed |
| US-5451622-A | Oil and water repellant, antisoiling fibers and films | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1995-09-19 | — | — | US | disclosed |
| US-5411576-A | Polypropylene fibers and melt processable fluoeochemical additive | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1995-05-02 | — | — | US | disclosed |
| EP-0616831-A1 | Oily mist resistant electret filter media | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1994-09-28 | — | — | EP | disclosed |
| JP-H06184354-A | COMPOSITION COMPRISING THERMOPLASTIC POLYMER AND FLUOROCHEMICAL PIPERAZINE COMPOUND | MINNESOTA MINING & MFG CO <3M> | 1994-07-05 | — | — | JP | disclosed |
| EP-0592884-A1 | Composition comprising thermoplastic polymer and fluorochemical piperazine compound | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1994-04-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060093554-A1 | Galenical formulations | GALC, GALR2, GALR1 | KDM4E 4212/4885CA2 2890/4885CA1 2871/4885 |
| US-20050147563-A1 | Metal complexes that contain perfluoroalkyl, process for their production and their use in NMR diagnosis | FABP1, FLOT1, AFF1 | KDM4E 4553/4885CA2 1733/4885CA1 2320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.